Pharming Group N.V. (PHAR) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Pharming Group Nv.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.133 Thank you, operator. Good morning and good afternoon, everyone, and welcome to 00:00:05.133 -- 00:00:09.153 our Q2 2026 earning calls. 00:00:09.154 -- 00:00:14.475 I'll be joined on this call today by Leverne Marsh, our chief commercial officer, 00:00:14.475 -- 00:00:19.597 Anurag Relan, our chief medical officer, and Kenneth Lynard, our 00:00:19.597 -- 00:00:22.597 chief financial officer. 00:00:23.438 -- 00:00:28.600 In this call, we will be making forward-looking statements that are based upon our current 00:00:28.600 -- 00:00:33.656 insights and plans. As you know, this may differ from 00:00:33.656 -- 00:00:36.056 future results. 00:00:37.917 -- 00:00:43.759 As you saw in today's press release, while we lowered our full-year revenue guidance, 00:00:43.759 -- 00:00:48.821 we are encouraged by the resilience of Reconest with robust underlying demand 00:00:48.821 -- 00:00:50.702 indicators. 00:00:50.702 -- 00:00:55.563 Joe and Jack continue to deliver strong growth, and we are approaching a number of significant 00:00:55.563 -- 00:00:57.464 near-term catalysts. 00:00:57.464 -- 00:01:02.675 Before I go into more detail on the quarter, Let me take a step back and 00:01:02.675 -- 00:01:09.598 put these developments into the context of the ongoing transformation of farming. 00:01:09.598 -- 00:01:14.880 We are evolving farming into a more diversified rare disease company 00:01:14.880 -- 00:01:19.441 with an increasingly attractive long-term growth profile. 00:01:19.482 -- 00:01:22.464 This is supported by three key pillars. 00:01:22.464 -- 00:01:27.406 Ruconest, which provides a durable source of cash flow. 00:01:27.406 -- 00:01:33.590 Johanja, a high growth asset still early in the cycle 00:01:33.590 -- 00:01:38.635 with significant c...